GlassScriptPhysician profile
Elizabeth J Anderson
NPI 1265450415
$3,029.39
in general payments reported to CMS, 2019-2025
20 companies · $570 in 2025
The $570 reported for 2025 was less than what a typical Procedural Dermatology provider received nationally (typical 2025 total: $599).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $191 · 2020: $217 · 2021: $319 · 2022: $549 · 2023: $715 · 2024: $469 · 2025: $570.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,385 · Education: $367.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,385.24 |
| Education | $367.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $788.52 | 2020-2025 | Skyrizi, Rinvoq |
| Novartis Pharmaceuticals Corporation | $466.71 | 2019-2025 | |
| Janssen Biotech, INC. | $454.88 | 2020-2025 | Tremfya |
| E.R. Squibb & Sons, L.L.C. | $213.84 | 2022-2024 | Sotyktu |
| Sun Pharmaceutical Industries INC. | $210.93 | 2019-2025 | Winlevi, Absorica Ld |
| Pfizer INC. | $180.29 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $153.56 | 2023-2024 | Dupixent, Libtayo |
| Leo Pharma INC. | $118.17 | 2019-2023 | Adbry |
| Galderma Laboratories, L.P. | $108.27 | 2019-2025 | Nemluvio, Aklief |
| Dermavant Sciences, INC. | $59.42 | 2023 | Vtama |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $50.05 | 2019-2020 | |
| Ani Pharmaceuticals, INC. | $48.92 | 2024-2025 | Purified Cortrophin Gel |
| Genzyme Corporation | $47.90 | 2023-2024 | |
| Helsinn Therapeutics (U.S.), INC. | $25.13 | 2019-2021 | |
| Amgen INC. | $20.83 | 2025 | Otezla |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Almirall LLC | $18.93 | 2025 | Klisyri |
| Organon LLC | $18.59 | 2025 | Vtama |
| Genentech USA, INC. | $16.96 | 2023 | Erivedge |
| Lilly USA, LLC | $13.94 | 2021 | |
| Incyte Corporation | $13.55 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Elizabeth Anderson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.